12:00 AM
 | 
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ME-344: Phase I started

Marshall Edwards began an open-label, dose-escalation, U.S. Phase I trial to evaluate once-weekly 1.2, 2.5, 5, 10 and 20 mg/kg IV ME-344 for the first 3 weeks...

Read the full 114 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >